Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors

  • Authors:
    • Henriette J.G. Arts
    • Steven De Jong
    • Harry Hollema
    • Klaske A. Ten Hoor
    • Elisabeth G.E. De Vries
    • Ate G.J. Van der Zee
  • View Affiliations

  • Published online on: February 1, 2005     https://doi.org/10.3892/ijo.26.2.379
  • Pages: 379-384
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Drug resistance in ovarian cancer treatment urges the exploration of new targets for drugs against this malignancy. Fas is a cell membrane receptor which, after engagement with Fas ligand (FasL), triggers apoptotic death. In this study Fas and FasL levels in cyst fluids and sera of patients with benign, borderline and malignant ovarian tumors and in corresponding tumors are determined. Fas and FasL were determinded by ELISA and immunohistochemistry in 30 patients with benign, 5 patients with borderline and 24 patients with malignant epithelial ovarian tumors. In serum there were no differences in median Fas levels, while median FasL levels were higher in healthy women (p=0.02). In malignant cyst fluids, median Fas levels where higher compared to benign cyst fluids (p<0.01). FasL immunostaining was more frequent in malignant ovarian tumors (p=0.002). In conclusion, serum Fas or FasL levels do not seem useful markers. Elevated Fas and equal FasL levels in malignant cyst fluids, suggest an increased production of Fas, and not of FasL by malignant cells. High expression of both Fas and FasL, in malignant ovarian tumors present Fas/FasL as an interesting route to explore for innovative cancer therapy.

Related Articles

Journal Cover

February 2005
Volume 26 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Arts HJ, De Jong S, Hollema H, Ten Hoor KA, De Vries EG and Van der Zee AG: Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors. Int J Oncol 26: 379-384, 2005.
APA
Arts, H.J., De Jong, S., Hollema, H., Ten Hoor, K.A., De Vries, E.G., & Van der Zee, A.G. (2005). Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors. International Journal of Oncology, 26, 379-384. https://doi.org/10.3892/ijo.26.2.379
MLA
Arts, H. J., De Jong, S., Hollema, H., Ten Hoor, K. A., De Vries, E. G., Van der Zee, A. G."Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors". International Journal of Oncology 26.2 (2005): 379-384.
Chicago
Arts, H. J., De Jong, S., Hollema, H., Ten Hoor, K. A., De Vries, E. G., Van der Zee, A. G."Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors". International Journal of Oncology 26, no. 2 (2005): 379-384. https://doi.org/10.3892/ijo.26.2.379